Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 26;9(8):e003132. doi: 10.1136/jitc-2021-003132

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

SVMAV promoted DC functions in vitro. (A) FITC fluorescence intensity of BMDCs with different treatments. (B) Frequency of CD11c⁺CD80⁺SIINFEKL⁺ BMDCs after different treatments. (C) Schematic illustration of the experimental design for cytolytic activity analysis of splenocytes primed by BMDCs. (D) The cytotoxicity of BMDCs treated with different formulations of vaccines was assessed by the LDH assays. (E) The viability of the remaining B16/F10-OVA cells was measured by the CCK8 assay. (F) Representative Photographs of the remaining B16/F10-OVA cells stained with crystal violet for different groups. Data are displayed as mean±SD. *P<0.05, **p<0.01, ****p<0.0001. BMDCs, bone marrow-derived dendritic cells; DC, dendritic cell; FITC, fluorescein isothiocyanate; LDH, lactate dehydrogenase; OVA, ovalbumin; SVMAV, self-assembling vehicle-free multicomponent antitumor nanovaccine.